Older patients (aged ≥65 years) with glioblastoma have a worse prognosis than younger patients and a median overall survival of 6–9 months. 3,4-Dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-DOPA) PET sensitively and specifically identifies metabolically active glioblastoma for preferential targeting. Proton beam therapy potentially improves quality of life (QOL) by sparing more healthy brain tissue than photon radiotherapy. With improved targeting and the dosimetric advantages of proton beam therapy, we aimed to test whether hypofractionated proton beam therapy could improve survival and QOL in older patients with glioblastoma.

中文翻译：

---

针对 65 岁及以上新诊断的胶质母细胞瘤患者的短程大分割质子束治疗，结合 18F-DOPA PET 和对比增强 MRI 靶向：一项单臂 2 期试验


患有胶质母细胞瘤的老年患者 （≥65 岁） 的预后比年轻患者更差，中位总生存期为 6-9 个月。3,4-二羟基-6-[18F]氟-L-苯丙氨酸 （18F-DOPA） PET 可灵敏且特异性地识别代谢活跃的胶质母细胞瘤，以优先靶向。质子束治疗比光子放射治疗保留更多健康的脑组织，从而可能改善生活质量 （QOL）。随着质子束治疗的靶向性和剂量学优势的提高，我们旨在测试大分割质子束治疗是否可以提高老年胶质母细胞瘤患者的生存率和 QOL。